Latest Licensing Agreements News

Neurizon Therapeutics has secured FDA clearance to resume clinical trials for its lead ALS drug NUZ-001, alongside a $5.2 million capital raise and a key licensing deal with Elanco Animal Health. These developments position the company for a critical growth phase in neurodegenerative disease therapeutics.

AdAlta Limited has made significant progress in its 'East to West' cellular immunotherapy strategy, advancing licensing negotiations for its first CAR-T product and raising $1.6 million through placements to bolster its financial position.

Algorae Pharmaceuticals has broadened its commercial footprint in Australia and New Zealand through key licensing agreements, while advancing its AI-driven drug discovery platform and strengthening leadership.

Starpharma has secured two major partnership agreements with Genentech and Radiopharm Theranostics, unlocking significant upfront payments and milestone potential while advancing its clinical pipeline.

Canadian Phosphate Limited has bolstered its balance sheet through the sale of its pelleting plant and reported improved cash flow despite permitting setbacks in British Columbia. The company is strategically positioned to capitalize on growing North American demand for domestically sourced phosphate amid global supply disruptions.

Cambium Bio has locked in a significant R&D tax rebate and forged three strategic partnerships, underpinning its Phase 3 clinical trials for its lead ophthalmology biologic. The company’s recent capital raise further strengthens its runway as it prepares for pivotal trial milestones.

Audeara Ltd has reported a remarkable 111% revenue increase in Q1 FY26, driven by strong growth in its technology division and key international partnerships in China and Japan. The company is advancing towards cashflow breakeven with improved cash management and expanding global reach.

Firebrick Pharma reports a $1.94 million cash reserve after a $1.4 million placement, supporting expanded Nasodine sales across Southeast Asia and the US. Board changes and increased operational costs mark a pivotal quarter for the pharmaceutical innovator.

Weebit Nano has reported a fourfold revenue increase in FY25, driven by a landmark licensing agreement with semiconductor giant onsemi and key automotive-grade qualification for its ReRAM technology.

Weebit Nano has reported a record quarter with A$7.3 million in customer receipts, securing three key product agreements and progressing critical technology milestones at leading semiconductor fabs.

archTIS has secured a A$250,000 contract to develop new features for its NC Protect product tailored to the U.S. Department of Defense’s Microsoft DoD365 environment, reinforcing its foothold in the U.S. defense sector.

Audeara Limited has landed its maiden purchase order for hearing aid technology in China, marking a pivotal step in its global expansion with production and launch planned for the final quarter of 2025.